ClinicalTrials.gg
CompletedNCT05727332VASSTUpdated Jun 26, 2025

Vascular Adaptations to Single-Sprint Training

An interventional study of Single-Sprint Training in Cardiovascular System, sponsored by University of Mississippi, Oxford. Completed at 1 site in United States. Open to participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-06-26.

Sponsored by University of Mississippi, Oxford · Not applicable, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
46
Allocation
Randomized
Ages
18 Years to 35 Years
Sex
All
01

Study summary

The long-term objective of this research line is to identify and implement an effective and feasible intervention capable of preventing and/or reducing the burden of cardiometabolic and obesity-related diseases that affect Mississippians and others. The pursuit of this long-term objective will begin with achieving the specific aims proposed in this pilot project, which are to determine the effect of single sprint training for improving (1) systemic macro-vascular function, (2) local and systemic micro-vascular function, and (3) cardiorespiratory fitness. These aims will be achieved using a randomized controlled trial whereby 40 males and females will be randomized into an intervention group (n=20) or time-matched negative control group (n=20). The intervention group will perform a single maximal effort sprint on a cycle ergometer for twenty seconds 3 days/week for 4 weeks and the control group will be asked to maintain pre-intervention habits/behavior over 4 weeks. All outcome measures are non-invasive, and will be assessed pre-, mid-, and post-intervention, with the exception of cardiorespiratory fitness, which will be measured pre- and post-. To achieve aim 1, brachial artery flow-mediated dilation via ultrasonography and systolic and diastolic blood pressure via automated oscillometry will be measured on the arm. To achieve aim 2, post-occlusive reactive hyperemia via near-infrared spectroscopy and reactive hyperemia via ultrasound will be measured in the arm and leg, respectively. To achieve aim 3, pulmonary gas exchange will be measured during a graded exercise test on a cycle ergometer. All outcomes will be compared across time between conditions and sex with a three-way Bayesian Repeated Measures ANOVA using pre-values as covariates and an uninformed prior. 95% credible intervals will also be calculated to power future investigations using this intervention. If the intervention is found effective, future studies will be conducted to determine the efficacy of the intervention in larger groups and more clinical populations, and to determine the mechanisms mediating the adaptations. If ineffective, the knowledge gained will be used to develop future interventions.

02

Conditions studied

  • Cardiovascular System

Keywords

  • Vascular
  • Cardiorespiratory Fitness
03

In context

Lead sponsor

University of Mississippi, Oxford is the lead sponsor of 12 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-35 years
  • Untrained (no regular exercise engagement for the previous 6 months)
  • Healthy enough to begin exercise (assessed via Physical Activity Readiness Questionnaire)

Exclusion criteria

Exclusion Criteria:

  • Illness/injury preventing cycling exercise
  • Prescribed medication to control heart rate
  • Prescribed medication to control blood pressure
  • Use of nicotine within the previous 6 months
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
46 participants (actual)

Study arms

  • Experimental
    Intervention

    The intervention group will perform a single maximal effort sprint on a cycle ergometer for twenty seconds 3 days/week for 4 weeks.

    Behavioral: Single-Sprint Training

  • No intervention
    Time-Matched Control

    The control group will be asked to maintain pre-intervention habits/behavior over 4 weeks.

Interventions

  • BehavioralSingle-Sprint Training

    A single maximal effort sprint on a cycle ergometer for twenty seconds 3 days/week for 4 weeks

06

What researchers measure

Primary outcomes

  1. Change from baseline systemic macrovascular function at 2 weeks and 4 weeks

    Systemic macrovascular changes will be quantified by measuring 1) brachial artery flow-mediated dilation via vascular ultrasound, and 2) resting brachial blood pressure via a standard automated blood pressure cuff.

    Time frame: week 0, week 2, and week 4

  2. Change from baseline local and systemic microvascular function at 2 weeks and 4 weeks

    Systemic changes in microvascular endothelial function will be quantified by using the post-occlusive reactive hyperemia technique in the arm. Local microvascular function will be measured using the passive leg movement technique for reactive hyperemia and post-occlusive reactive hyperemia in the leg.

    Time frame: week 0, week 2, and week 4

Secondary outcomes

  1. Change from baseline maximal oxygen consumption at 2 weeks and 4 weeks

    To assess changes in cardiorespiratory fitness, pulmonary gas exchange data will be collected during a maximal graded exercise test on a cycle ergometer. VO2max and ventilation thresholds will be reported in accordance with current guidelines.

    Time frame: week 0, week 2, and week 4

07

Study locations

1 site
  • University of Mississippi
    University, Mississippi 38677, United States
08

References and documents

Individual participant data

Plan to share: No — There is no current plan to share individual data outside of the investigators responsible for conducting the study. If data are requested, they will only be shared after being de-identified, unless otherwise required by law.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2023 to primary completion in Jul 2024, 13 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 26, 2023
First posted
Feb 14, 2023
StartActual
Jun 5, 2023
Primary completionActual
Jul 31, 2024
CompletionActual
Dec 5, 2024
Last update
Jun 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05727332
Lead sponsor
University of Mississippi, Oxford
Responsible party
Matthew Jessee (Assistant Professor, University of Mississippi, Oxford) — Principal investigator
First posted
Feb 14, 2023
Start date
Jun 5, 2023
Primary completion
Jul 31, 2024
Completion
Dec 5, 2024
Last update
Jun 26, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion